These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1477008)

  • 41. Blood and bone marrow dosimetry in radioiodine therapy of differentiated thyroid cancer after stimulation with rhTSH.
    Lassmann M; Hänscheid H; Reiners C; Thomas SR
    J Nucl Med; 2005 May; 46(5):900-1; author reply 901. PubMed ID: 15872369
    [No Abstract]   [Full Text] [Related]  

  • 42. [Polycytostatic treatment of highly aggressive thyroid malignomas].
    Zechmann W; Riccabona G
    Z Allgemeinmed; 1975 Oct; 51(29):1304-7. PubMed ID: 1199156
    [No Abstract]   [Full Text] [Related]  

  • 43. Guidelines for the use of radio-iodine, thyroid hormone, and treatment of metastatic disease in patients with differentiated thyroid cancer.
    Paloyan E; Walker RP; Lawrence AM
    Surg Oncol Clin N Am; 1998 Oct; 7(4):665-80. PubMed ID: 9735128
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Radioiodine therapy for lung and bone metastasis of differentiated thyroid cancer].
    Inagaki T; Shibata T; Iida Y; Kasagi K; Endo K; Konishi J; Torizuka K
    Nihon Igaku Hoshasen Gakkai Zasshi; 1985 Mar; 45(3):518-24. PubMed ID: 4011426
    [No Abstract]   [Full Text] [Related]  

  • 45. Thyroid remnant ablation following administration of a diagnostic dose of iodine-131 under thyrogen stimulation.
    Wu D; Fink-Bennett D; Campbell J
    Thyroid; 2014 May; 24(5):924-5. PubMed ID: 24483713
    [No Abstract]   [Full Text] [Related]  

  • 46. The role of external radiation in the management of papillary and follicular thyroid cancer.
    Simpson WJ; Carruthers JS
    Am J Surg; 1978 Oct; 136(4):457-60. PubMed ID: 707725
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term survival and low effective cumulative radioiodine doses to achieve remission in patients with 131Iodine-avid lung metastasis from differentiated thyroid cancer.
    Pitoia F; Bueno F; Cross G
    Clin Nucl Med; 2014 Sep; 39(9):784-90. PubMed ID: 24999689
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The use of 131I in the combined modality therapy of highly differentiated cancer of the thyroid gland].
    Baranauskas ZL; Mamontov VV; Valutskas KK
    Med Radiol (Mosk); 1989 Oct; 34(10):31-4. PubMed ID: 2811625
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
    Jarzab B; Handkiewicz-Junak D; Wloch J
    Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differentiated thyroid carcinoma (DTC) in the elderly: disease outcome, therapeutic approach, and long-term results in a group of 314 patients.
    Girelli ME; Casara D; Rubello D; Mazzarotto R; Saladini G; Busnardo B
    J Endocrinol Invest; 1999; 22(10 Suppl):45-6. PubMed ID: 10727040
    [No Abstract]   [Full Text] [Related]  

  • 51. Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.
    Bulotta S; Celano M; Costante G; Russo D
    Endocrine; 2016 May; 52(2):214-21. PubMed ID: 26690657
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.
    Sampson E; Brierley JD; Le LW; Rotstein L; Tsang RW
    Cancer; 2007 Oct; 110(7):1451-6. PubMed ID: 17705176
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy in a real-life scenario.
    Campennì A; Giovanella L; Pignata SA; Violi MA; Siracusa M; Alibrandi A; Moleti M; Amato E; Ruggeri RM; Vermiglio F; Baldari S
    Nucl Med Commun; 2015 Nov; 36(11):1100-6. PubMed ID: 26302462
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Measurement of thyroglobulin or 131iodine scintigraphy in the after-care of patients with differentiated thyroid cancer].
    Schatz H; Horn W; Grebe SF; Müller H
    Dtsch Med Wochenschr; 1983 Nov; 108(45):1737-8. PubMed ID: 6313317
    [No Abstract]   [Full Text] [Related]  

  • 55. Limitations and indications in the treatment of cancer of the thyroid with radioactive iodine.
    RAWSON RW; RALL JE; PEACOCK W
    J Clin Endocrinol Metab; 1951 Oct; 11(10):1128-42. PubMed ID: 14873783
    [No Abstract]   [Full Text] [Related]  

  • 56. Salivary gland dysfunction following radioactive iodine therapy.
    Wiesenfeld D; Webster G; Cameron F; Ferguson MM; MacFadyen EE; MacFarlane TW
    Oral Surg Oral Med Oral Pathol; 1983 Feb; 55(2):138-41. PubMed ID: 6572864
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Combined treatment of thyroid cancer metastases to the lungs in children and young people].
    Kiseleva ES; Skorobogatov NM; Zvekotkina LS; Voronetskiĭ IB
    Med Radiol (Mosk); 1987 Mar; 32(3):7-10. PubMed ID: 3561214
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Well differentiated thyroid cancer: are we over treating our patients?
    Nixon IJ; Shah JP
    Eur J Surg Oncol; 2014 Feb; 40(2):129-32. PubMed ID: 24373300
    [No Abstract]   [Full Text] [Related]  

  • 59. Genetic risk assessment after iodine-131 exposure: an opportunity and obligation for nuclear medicine.
    Dottorini ME
    J Nucl Med; 1996 Apr; 37(4):612-5. PubMed ID: 8691250
    [No Abstract]   [Full Text] [Related]  

  • 60. Historical note: TSH suppression for thyroid cancer.
    Hurley JR
    Thyroid; 2011 Nov; 21(11):1175-6. PubMed ID: 22050035
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.